Form 4: Agios Pharmaceuticals Director Exercises Stock Options and Receives Shares

Director David P. Schenkein exercised restricted stock units to acquire 3,388 shares of Agios Pharmaceuticals common stock on June 13, 2024.

Summary

• On June 13, 2024, David P. Schenkein, a director of Agios Pharmaceuticals, exercised restricted stock units.
• This transaction resulted in the acquisition of 3,388 shares of common stock.
• The shares were acquired at a price of $0 per share as part of the vesting of restricted stock units.
• Following the transaction, Schenkein directly owns 126,242 shares of common stock.
• Schenkein also indirectly owns 270,772 shares through the David P. Schenkein 2004 Revocable Trust and 79,082 shares through the Amy P. Schenkein 2004 Revocable Trust.
• The restricted stock units were granted on June 13, 2023, and vested in full on June 13, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard transaction related to executive compensation. The director exercising options suggests confidence, but it's not a major event.

Positives

• The exercise of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the ownership changes of company executives and directors.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it slightly increases the number of outstanding shares.

Key Dates